Best Practice & Research Clinical Rheumatology
Volume 22, Issue 2 , Pages 325-337 , April 2008

Spondyloarthropathies: progress and challenges

  • Dirk Elewaut, MD, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author. Ghent University Hospital, Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, 185 De Pintelaan, B-9000 Ghent, Belgium. Tel.: +32 9 240 22 40; Fax: +32 9 240 38 03.

References 

  1. Gran JT, Husby G, Hordvik M. Prevelance of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Annals of the Rheumatic Diseases. 1985;44:359–367
  2. Saraux A, Guillemin F, Guggenbuhl P, et al. Prevalence of spondyloarthropathies in France: 2001. Annals of the Rheumatic Diseases. 2005;64(10):1431–1435
  3. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis & Rheumatism. 1998;41(1):58–67
  4. Davis JC, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis & Rheumatism. 2003;48(11):3230–3236
  5. Kruithof E, Van den Bosch F, Baeten D, et al. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Annals of the Rheumatic Diseases. 2002;61(3):207–212
  6. Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis & Rheumatism. 2002;46(3):755–765
  7. D'Haens G, Swijsen C, Noman M, et al. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. American Journal of Gastroenterology. 2001;96(9):2564–2568
  8. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121(5):1088–1094
  9. Baeten D, De Keyser F. The histopathology of spondyloarthropathy. Current Molecular Medicine. 2004;4(1):1–12
  10. Baeten D, Demetter P, Cuvelier C, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Annals of the Rheumatic Diseases. 2000;59(12):945–953
  11. Ceponis A, Konttinen YT, MacKevicius Z, et al. Aberrant vascularity and von Willebrand factor distribution in inflamed synovial membrane. The Journal of Rheumatology. 1996;23(11):1880–1886
  12. Reece RJ, Canete JD, Parsons WJ, et al. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis & Rheumatism. 1999;42(7):1481–1484
  13. Veale D, Yanni G, Rogers S, et al. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis & Rheumatism. 1993;36(7):893–900
  14. Elewaut D, De Keyser F, Van Den Bosch F, et al. Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. The Journal of Rheumatology. 1998;25(10):1932–1937
  15. Baeten D, Van Damme N, Van den Bosch F, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Annals of the Rheumatic Diseases. 2001;60(8):750–755
  16. Canete JD, Martinez SE, Farres J, et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Annals of the Rheumatic Diseases. 2000;59(4):263–268
  17. Kraan MC, Haringman JJ, Post WJ, et al. Immunohistological analysis of synovial tissue for differential diagnosis in early arthritis. Rheumatology (Oxford). 1999;38(11):1074–1080
  18. Smeets TJ, Dolhain RJ, Breedveld FC, et al. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. The Journal of Pathology. 1998;186(1):75–81
  19. Kruithof E, Baeten D, Van den Bosch F, et al. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Annals of the Rheumatic Diseases. 2005;64(4):529–536
  20. Baeten D, Demetter P, Cuvelier CA, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. The Journal of Pathology. 2002;196(3):343–350
  21. Baeten D, Kruithof E, De Rycke L, et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Research & Therapy. 2005;7(2):R359–R369
  22. Rufai A, Ralphs JR, Benjamin M. Structure and histopathology of the insertional region of the human Achilles tendon. Journal of Orthopaedic Research. 1995;13(4):585–593
  23. Benjamin M, McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. Journal of Anatomy. 2001;199(Pt 5):503–526
  24. Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis. Annals of the Rheumatic Diseases. 1971;30(3):213–223
  25. Benjamin M, Moriggl B, Brenner E, et al. The ‘enthesis organ’ concept: why enthesopathies may not present as focal insertional disorders. Arthritis & Rheumatism. 2004;50(10):3306–3313
  26. Moriggl B, Jax P, Milz S, et al. Fibrocartilage at the entheses of the suprascapular (superior transverse scapular) ligament of man–a ligament spanning two regions of a single bone. Journal of Anatomy. 2001;199(Pt 5):539–545
  27. McGonagle D, Lories RJ, Tan AL, et al. The concept of a ‘synovio-entheseal complex’ and its implications for understanding of inflammation and damage in psoriatic arthritis and beyond. Arthritis & Rheumatism. 2007 Aug;56(8):2482–2491[Review]
  28. Benjamin M, Toumi H, Suzuki D, et al. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis & Rheumatism. 2007;56(1):224–233
  29. Francois RJ, Gardner DL, Degrave EJ, et al. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis & Rheumatism. 2000;43(9):2011–2024
  30. Muche B, Bollow M, Francois RJ, et al. Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis & Rheumatism. 2003;48(5):1374–1384
  31. De Keyser F, Elewaut D, De Vos M, et al. Bowel inflammation and the spondyloarthropathies. Rheumatic Diseases Clinics of North America. 1998;24:785–813
  32. Moller P, Vinje O, Kass E, et al. The distribution of clinical findings in Bechterew's syndrome (ankylosing spondylitis) suggests distinct genetic subgroups. Clinical Genetics. 1982;22(4):151–159
  33. Leirisalo-Repo M, Turunen U, Stenman S, et al. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis & Rheumatism. 1994;37(1):23–31
  34. Vander Cruyssen B, Peeters H, Hoffman IE, et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients. Clinical and Experimental Immunology. 2005;140(2):354–359
  35. Mielants H, Veys EM, De Vos M, et al. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. The Journal of Rheumatology. 1995;22(12):2266–2272
  36. Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. The Journal of Rheumatology. 1995;22(12):2273–2278
  37. Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. The Journal of Rheumatology. 1995;22(12):2279–2284
  38. De Vos M, Mielants H, Cuvelier C, et al. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology. 1996;110(6):1696–1703
  39. Cuvelier C, Barbatis C, Mielants H, et al. Histopathology of intestinal inflammation related to reactive arthritis. Gut. 1987;28(4):394–401
  40. Peeters H, Vander Cruyssen B, Laukens D, et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Annals of the Rheumatic Diseases. 2004;63(9):1131–1134
  41. Palm O, Moum B, Ongre A, et al. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). The Journal of Rheumatology. 2002;29(3):511–515
  42. Purrmann J, Zeidler H, Bertrams J, et al. HLA antigens in ankylosing spondylitis associated with Crohn's disease. Increased frequency of the HLA phenotype B27, B44. The Journal of Rheumatology. 1988;15(11):1658–1661
  43. de Vlam K, Mielants H, Cuvelier C, et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. The Journal of Rheumatology. 2000;27(12):2860–2865
  44. Steer S, Jones H, Hibbert J, et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. The Journal of Rheumatology. 2003;30(3):518–522
  45. Reveille JD. Major histocompatibility genes and ankylosing spondylitis. Best Practice & Research. Clinical Rheumatology. 2006;20(3):601–609
  46. Schroder M, Kaufman RJ. ER stress and the unfolded protein response. Mutation Research. 2005;569(1–2):29–63
  47. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. The Journal of Experimental Medicine. 1994;180(6):2359–2364
  48. Taurog JD, Maika SD, Simmons WA, et al. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. Journal of Immunology (Baltimore, Md.: 1950). 1993;150(9):4168–4178
  49. Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell. 1990;63(5):1099–1112
  50. Tran TM, Dorris ML, Satumtira N, et al. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis & Rheumatism. 2006;54(4):1317–1327
  51. Enlow RW, Bias WB, Arnett FC. The spondylitis of inflammatory bowel disease. Evidence for a non-HLA linked axial arthropathy. Arthritis & Rheumatism. 1980;23(12):1359–1365
  52. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411(6837):603–606
  53. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411(6837):599–603
  54. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. The Lancet. 2001;357(9272):1925–1928
  55. Laukens D, Peeters H, Marichal D, et al. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Annals of the Rheumatic Diseases. 2005;64(6):930–935
  56. Miceli-Richard C, Zouali H, Lesage S, et al. CARD15/NOD2 analyses in spondylarthropathy. Arthritis & Rheumatism. 2002;46(5):1405–1406
  57. Crane AM, Bradbury L, van Heel DA, et al. Role of NOD2 variants in spondylarthritis. Arthritis & Rheumatism. 2002;46(6):1629–1633
  58. Laukens D, Peeters H, Cruyssen BV, et al. Altered gut transcriptome in spondyloarthropathy. Annals of the Rheumatic Diseases. 2006;65(10):1293–1300
  59. Tuzun A, Erdil A, Inal V, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clinical Biochemistry. 2002;35(7):569–572
  60. Aimone-Gastin I, Cable S, Keller JM, et al. Studies on peroxisomes of colonic mucosa in Crohn's disease. Digestive Diseases and Sciences. 1994;39(10):2177–2185
  61. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461–1463
  62. Peyrin-Biroulet L, Parmentier-Decrucq E, Branche J, et al. IL-23R, a novel susceptibility gene for inflammatory bowel disease. Médecine Sciences. 2007;23(3):250–252
  63. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. The Journal of Clinical Investigation. 2006;116(5):1310–1316
  64. Rahman P, Inman RD, Gladman DD, et al. Association of IL-23R variants and ankylosing spondylitis. Annals of the Rheumatic Diseases. 2007;66(Suppl. II):83
  65. Reveille JD, Zhou X, Bradbury LA, et al. IL-23R is a major determinant of ankylosing spondylitis risk – the TASC study. Annals of the Rheumatic Diseases. 2007;66(Suppl. II):112
  66. Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Human Genetics. 2007 Sep;122(2):201–206
  67. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. The Lancet. 1994;344(8930):1105–1110
  68. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. The Lancet. 1999;354(9194):1932–1939
  69. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. The New England Journal of Medicine. 2000;343(22):1594–1602
  70. Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis & Rheumatism. 2006;54(3):702–710
  71. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis & Rheumatism. 2004;50(11):3432–3443
  72. Manadan AM, James N, Block JA. New therapeutic approaches for spondyloarthritis. Current Opinion in Rheumatology. 2007;19(3):259–264
  73. Baraliakos X, Listing J, Rudwaleit M, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Annals of the Rheumatic Diseases. 2005;64(10):1462–1466
  74. Braun J, Landewe R, Hermann KG, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis & Rheumatism. 2006;54(5):1646–1652
  75. Braun J, Landewe R, Hermann KG, et al. Sustained reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab. Annals of the Rheumatic Diseases. 2007;66(Suppl. II):85
  76. Van der Heijde D, Landewe R, Deodar A, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment not inhibited with infliximab. Annals of the Rheumatic Diseases. 2007;66(Suppl. II):85
  77. Van der Heijde D, Landewe R, Tsuji W. Two-year etanercept therapy does not inhibit radiographic progression in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases. 2006;65(Suppl. II):81
  78. Wanders A, Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis & Rheumatism. 2005;52(6):1756–1765
  79. Lories RJ, Derese I, de Bari C, et al. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis & Rheumatism. 2007;56(2):489–497
  80. Bafico A, Liu G, Yaniv A, et al. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nature Cell Biology. 2001;3(7):683–686
  81. Glinka A, Wu W, Delius H, et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 1998;391(6665):357–362
  82. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Natural Medicines. 2007;13(2):156–163
  83. Schett G, Landewe R, van der Heijde D. Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?. Annals of the Rheumatic Diseases. 2007;66(6):709–711
  84. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Annals of the Rheumatic Diseases. 2006;65(12):1631–1634
  85. Doubremelle M, Bourreille A, Zerbib F, et al. Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study. Gastroenterologie Clinique Et Biologique. 2002;26(11):973–979
  86. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. The Lancet. 2002;359(9317):1541–1549
  87. Sandborn WJ, Hanauer S, Loftus EV, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. American Journal of Gastroenterology. 2004;99(10):1984–1989
  88. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflammatory Bowel Diseases. 2004;10(4):333–338
  89. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. American Journal of Gastroenterology. 2005;100(1):75–79
  90. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–333
  91. Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis & Rheumatism. 2007;57(4):639–647
  92. Haibel H, Rudwaleit M, Brandt HC, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis & Rheumatism. 2006;54(2):678–681
  93. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism. 2006;54(7):2136–2146
  94. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124(7):1774–1785
  95. Boirivant M, Marini M, Di Felice G, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology. 1999;116(3):557–565
  96. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. Journal of Immunology (Baltimore, Md.: 1950). 1999;163(2):1081–1090

PII: S1521-6942(08)00012-0

doi: 10.1016/j.berh.2008.01.011

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 2 , Pages 325-337 , April 2008

Article Tools